原始出處紀錄
重大申請已送件
Metagenomi: MGX-001 IND 提交計畫於 2026 年第 4 季
該公司確認其主要血友病 A 計畫仍按計畫進行，預計於 2026 年第 4 季提交 IND。此提交旨在使 2027 年進行首次人體試驗，但需獲得監管核准。
關鍵事實
來源摘錄
EX-99.1 2 mgx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency $140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its p